Related Experiment Video

Updated: Apr 21, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Targeting the estrogen pathway for the treatment and prevention of lung cancer

Timothy F Burns1, Laura P Stabile2

  • 1Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, Hillman Cancer Center Research Pavilion, 2.18e, 5117 Centre Avenue, Pittsburgh, PA 15213-1863, USA.

Lung Cancer Management
|November 15, 2014
PubMed

Insights

Estrogen signaling is a key factor in non-small-cell lung cancer, offering a new therapeutic target. Hormonal therapies show promise in inhibiting tumor growth and preventing lung cancer development.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Estrogen signaling plays a role in non-small-cell lung cancer (NSCLC) development and progression.
  • This pathway presents a novel therapeutic target for lung cancer treatment.
  • Epidemiological data, preclinical research, and clinical trials support targeting estrogen in NSCLC.

Purpose of the Study:

  • To evaluate the role of estrogen signaling in non-small-cell lung cancer.
  • To explore the potential of hormonal therapies as a treatment strategy for NSCLC.
  • To identify patient populations that may benefit from estrogen-modulating agents.

Main Methods:

  • Review of epidemiological evidence.
  • Analysis of in vitro and in vivo preclinical studies.
  • Examination of data from clinical trials on hormonal strategies for advanced NSCLC.

Main Results:

  • Antiestrogens and estrogen synthesis inhibitors demonstrated efficacy in inhibiting lung tumor growth and preventing tumorigenesis in preclinical models.
  • Two clinical trials investigating hormonal strategies in advanced NSCLC yielded promising outcomes.

Conclusions:

  • The estrogen signaling pathway is a viable therapeutic target for non-small-cell lung cancer.
  • Hormonal therapies show potential for treating and preventing NSCLC.
  • Further research should focus on identifying specific patient groups for targeted hormone modulation therapy for earlier intervention or chemoprevention.

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.6K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K